Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study.

Front Oncol · 2022 · PMC9722716 · PMID 36483043

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

There was also an increasing trend of OS benefit that the HR was 0.75 (95% CI, 0.28–2.01) and 0.67 (95% CI, 0.29–1.55) at the two timepoints of the analyses.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.